Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers

(2016) Peter C. Enzinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer

(2014) Valérie F. Cosson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Exposure–Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer

(2014) J Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

(2014) Lin Shen et al.   Gastric Cancer

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer

(2014) R. Garcia-Carbonero et al.   ONCOLOGIST

Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

(2013) Y. Feng et al.   CLINICAL CANCER RESEARCH

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

(2013) Florian Lordick et al.   LANCET ONCOLOGY

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

(2008) Salah-Eddin Al-Batran et al.   JOURNAL OF CLINICAL ONCOLOGY